LindaMarieSerranoMD

Dermatology • New Berlin, WI

Resident Physician

Join to view full profile

Dr. Serrano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Serrano's full profile

Already have an account?

Office
12901 W National Ave
New Berlin, WI 53151
Phone+1 262-787-5200

Fax+1 262-787-5299

Education & Training

Medical College of Wisconsin Affiliated HospitalsPost-Doctoral Fellowship, Dermatology, 2018
Northwestern Memorial HospitalPost-Doctoral Fellowship, 2016
Advocate Health Care/Advocate Lutheran General HospitalResidency, Internal Medicine, 2015 - 2016
University of Illinois College of MedicineClass of 2015

Certifications & Licensure

WI State Medical License 2020 - 2025
IL State Medical License 2015 - 2016
American Board of Dermatology Dermatology

Clinical Trials

Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma Start of enrollment: 2014 Nov 01
Unknown status
Phase 2
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma Start of enrollment: 2014 Nov 12
Completed
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Start of enrollment: 2015 Dec 01
Completed
Phase 3
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Start of enrollment: 2016 Feb 09
Completed
Phase 1
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Start of enrollment: 2017 Jan 01
Terminated
Phase 3
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Start of enrollment: 2017 Jun 29
Completed
Phase 3
A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption Start of enrollment: 2017 Feb 16
Terminated
Phase 2
A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients Start of enrollment: 2017 Oct 24
Completed
Phase 2
Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction Start of enrollment: 2017 Apr 11
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

8 citations
African American race is a risk factor for severe hidradenitis suppurativa.
Caden Ulschmid, Linda Serrano, Ruizhe Wu, Gretchen M Roth, Olayemi Sokumbi
International Journal of Dermatology. 2023-05-01
8 citations
Racial disparities of delay in diagnosis and dermatologic care for hidradenitis suppurativa.
Linda Serrano, Caden Ulschmid, Aniko Szabo, Gretchen Roth, Olayemi Sokumbi
Journal of the National Medical Association. 2022-12-01
3 citations
Risankizumab in moderate-to-severe plaque psoriasis.
Serrano L, Maloney, Kenneth B. Gordon
Immunotherapy. 2019-10-03

Journal Articles

Hemophagocytic Lymphohistiocytosis in Cutaneous T-cell Lymphoma
Jaehyuk Choi, Linda M Serrano, Jason B Kaplan, Barbara Pro, Joan Guitart, JAMA

LindaMarieSerranoMD

Dr. Serrano is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.